Fundz

Fundz Deep Dive

Everything you need to win Marcel Konrad — in one platform.

Who to reach, what to say, and why now on Marcel Konrad — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Marcel Konrad — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Octave Bioscience Appoints Marcel Konrad As Chief Financial Officer and Adds Several New Commercial Leaders

PRIVATEAug 07, 2024•almost 2 years ago

Position

Chief Financial Officer

Company

Octave Bioscience

Marcel Konrad
Menlo ParkBiotechnologyHealthcare

Description

Octave Bioscience, a leading precision care company, has appointed Marcel Konrad as Chief Financial Officer, who brings a distinguished track record in scaling high-growth therapeutic and diagnostic companies. The company has also made several new appointments of proven commercial leaders, including CEO Doug Biehn, Chief Revenue Officer Jeron Evans, and Chief Access Officer Debbie Ledet.

Company Information

Company

Octave Bioscience

Location

Menlo Park, California, United States

About

Octave Bioscience, Inc. is a commercial growth stage precision medicine company pioneering biomarker-driven solutions for neurodegenerative diseases, with an initial focus on Multiple Sclerosis, and Parkinson’s Disease in partnership with the Michael J. Fox Foundation. Octave’s comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Octave Bioscience's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.